The recent trend of betting on clinical trials through platforms such as Kalshi and Polymarket has been met with intense criticism, with many experts condemning the practice as ‘ghastly’ and unethical. These platforms, which allow users to wager on the outcome of clinical trials, have been accused of profiting from the suffering of patients and undermining the integrity of the scientific process. The criticism centers on the potential for these betting platforms to create perverse incentives, where the outcome of a trial is influenced by the desire to win a bet rather than to advance medical knowledge. Furthermore, the involvement of speculative betting in clinical trials raises concerns about the exploitation of vulnerable patients and the potential for data manipulation. As the debate surrounding these platforms continues to grow, it is likely that regulators and lawmakers will be forced to take action, potentially leading to stricter oversight and regulation of the industry. The outcome of this controversy will have significant implications for the future of clinical trials and the role of betting platforms in the scientific process.
On top of everything as it happens